Nektar Therapeutics
NKTR
Positions held
Your positionsNKTR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Nektar Therapeutics operates in the biotechnology sector, which is known for its potential to revolutionize healthcare through innovative therapies and treatments.
- The company has a strong recommendation of 'strong buy' from analysts, indicating positive sentiment about its future performance.
- Despite recent challenges, Nektar's revenue for 2025 was $55.232 million, showing a significant market presence.
- Nektar Therapeutics faces significant operational challenges, with an operating margin of -412.2% in the latest quarter.
- The company's net income has been consistently negative, totaling -276.056 million in 2023.
- Revenue decreased by 7% compared to the prior quarter, dropping from $11 million to $10 million.
Fundamentals
| Market cap | $1.39B | Enterprise value | $844.63M | Trailing P/E | — | Forward P/E | -4.00 |
| PEG | 0.31 | Price / book | 1.54 | Beta | 1.27 | Dividend yield | 0.00% |
| Revenue growth | -9.3% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -4.1% |
| Profit margin | -2.9% | ROE | -35.8% | ROA | -12.5% | Debt / equity | 0.15 |
| Current ratio | 10.42 | Free cash flow | -$134.77M | Analyst recommendation | strong_buy | Mean target | $141.40 |
| 52w high | $109.00 | 52w low | $33.40 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $10.1M | $10.9M | $21.8M | $11.8M | $11.2M | — |
| Op margin | -412.2% | -352.3% | -87.5% | -267.4% | -320.2% | — |
| Net income | -$40.6M | -$44.9M | -$36.1M | -$35.5M | -$41.6M | — |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | — |
| Gross profit | — | — | $21.8M | $11.8M | $11.2M | $10.5M |
| Operating income | -$41.8M | -$38.3M | -$19.1M | -$31.5M | -$35.8M | — |
- Revenue -7% vs prior quarter ($10M vs $11M).
- Gross margin 100% (was 100% prior quarter).
- Operating margin compressed to -412.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | — |
| Op margin | -236.8% | -132.0% | -150.0% | -261.0% | — |
| Net income | -$164M | -$119M | -$276M | -$368M | — |
| Gross margin | 100.0% | 68.8% | 62.5% | 76.5% | — |
| Gross profit | $55.2M | $67.7M | $56.4M | $70.4M | — |
| Operating income | -$131M | -$130M | -$135M | -$240M | — |
Headlines — watch
• [WARN · legal] Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
News
2026-10-07 · Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
2026-10-05 · EADV26: Key late-stage readouts from the conference
2026-10-01 · Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
2026-10-01 · NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
2026-10-01 · This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
2026-10-01 · Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
2026-10-01 · 3 Biotech Stocks Put Traders Are Targeting Today
2026-10-01 · /UPDATE -- Nektar Therapeutics/
2026-09-30 · Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2
2026-09-30 · How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors
2026-09-30 · What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?
Price (daily)
Full chart · RSI · MACD · patterns